Karyopharm files for Chapter 11 and names Ayrmid lead bidder in proposed merger
Business · First reported 2 Nov, 10:46 · Updated 16:25
Karyopharm says it will continue operating and developing treatments while it pursues a court-supervised restructuring that could result in a merger with Ayrmid. The proposal is subject to court approval, competing bids and other conditions.
- Karyopharm filed for Chapter 11 protection in the Southern District of Texas and reached a restructuring agreement naming Ayrmid as lead bidder in a court-supervised sale process.
- The company secured commitments for up to $55 million in financing from existing secured lenders, subject to court approval, to support operations during restructuring.
- Karyopharm expects the proposed merger to close in the first quarter of 2027, but the outcome depends on bankruptcy proceedings and other conditions.
Summary written by Lux AI from 2 articles
Key facts
- Financing commitment
- Up to $55 million from existing secured lenders, subject to court approval.
- Proposed closing
- First quarter of 2027, subject to court approval and other conditions.
- Court
- U.S. Bankruptcy Court for the Southern District of Texas.
Source spectrum
Left 0 · Centre 0 · Right 0 of 0 rated sources · +2 unrated
All coverage
Coverage over time
LeftCentreRight
Articles per hour since first reported, by side.
Ownership
- Unknown 100% (2)
Share of the 2 sources by owner type.